Key result
In patients with cardiac resynchronization therapy, the presence of subclinical atrial fibrillation independently increased the risk of silent ischemic brain lesions by 3.5 times (OR 3.555).
Why the study?
Does subclinical atrial fibrillation increase the risk of silent ischemic brain lesions in patients with cardiac resynchronization therapy?
Cohort (n=121)
No
Does subclinical atrial fibrillation increase the risk of silent ischemic brain lesions in patients with cardiac resynchronization therapy?
Effect estimate: OR 3.555 (95% CI 1.266-9.984)
Absolute Event Rate: 32.4% vs 11.5%
p-value: p=0.016
Subclinical atrial fibrillation and reduced left ventricular ejection fraction are independently associated with an increased risk of silent ischemic brain lesions in patients with cardiac resynchronization therapy.
Subclinical AF associated with silent lesions in CRT patients; hypothesis-generating for prospective intervention trials.
INTRODUCTION: There is insufficient research on the relationship between subclinical atrial fibrillation (SCAF) and silent ischemic brain lesions (IBLs). AIM: To investigate the relationship between SCAF and silent IBLs in patients with cardiac resynchronization therapy (CRT). MATERIAL AND METHODS: Of 720 CRT implanted patients in our department between 2012 and 2018, 121 patients who underwent elective cranial multi-slice computed tomography (MSCT) during their follow-up were included in our study. Atrial high-rate episodes (AHRE) were detected by the CRT device. Subclinical atrial fibrillation was defined as asymptomatic AHRE longer than 6 min and shorter than 24 h. A cranial MSCT scan was performed using a 128-section scanner with contiguous 2-5 mm axial images. Patients were divided into two groups - with and without silent IBL. RESULTS: < 0.05). In multivariate regression analysis, presence of SCAF and LVEF were found to be independent parameters predicting the risk of silent IBLs. According to this analysis, the presence of SCAF and every 1% decrease in LVEF were found to increase the risk of silent IBL by 3.5 times and 14.8%, respectively. CONCLUSIONS: Subclinical atrial fibrillation is independently associated with silent IBL presence. Patients with CRT should be closely monitored for SCAF. Patients diagnosed with SCAF should be evaluated for IBL development and treated with the appropriate oral anticoagulant.
No takes yet. Share an insight, caveat, or question.
İçen et al. (2018) conducted a cohort in Cardiac resynchronization therapy (CRT) (n=121). Subclinical atrial fibrillation (SCAF) vs. No SCAF was evaluated on Silent ischemic brain lesions (IBL) (OR 3.555, 95% CI 1.266-9.984, p=0.016). In patients with cardiac resynchronization therapy, the presence of subclinical atrial fibrillation independently increased the risk of silent ischemic brain lesions by 3.5 times (OR 3.555).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: